Antibacterial therapeutics for the treatment of chytrid infection in amphibians: Columbus's egg?

被引:10
|
作者
Muijsers, Mariska [1 ]
Martel, An [1 ]
Van Rooij, Pascale [1 ]
Baert, Kris [2 ]
Vercauteren, Griet [1 ]
Ducatelle, Richard [1 ]
De Backer, Patrick [3 ]
Vercammen, Francis [4 ]
Haesebrouck, Freddy [1 ]
Pasmans, Frank [1 ]
机构
[1] Univ Ghent, Fac Vet Med, Dept Pathol Bacteriol & Avian Dis, B-9820 Merelbeke, Belgium
[2] Medicem NV, B-9100 Niklaas, Belgium
[3] Univ Ghent, Fac Vet Med, Dept Pharmacol Pharm & Toxicol, B-9820 Merelbeke, Belgium
[4] Ctr Res & Conservat, Royal Zool Soc Antwerp, B-2018 Antwerp, Belgium
来源
BMC VETERINARY RESEARCH | 2012年 / 8卷
关键词
BATRACHOCHYTRIUM-DENDROBATIDIS; CHYTRIDIOMYCOSIS; TRIMETHOPRIM; TROPICALIS; DECLINES; FROGS; TIME;
D O I
10.1186/1746-6148-8-175
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Background: The establishment of safe and effective protocols to treat chytridiomycosis in amphibians is urgently required. In this study, the usefulness of antibacterial agents to clear chytridiomycosis from infected amphibians was evaluated. Results: Florfenicol, sulfamethoxazole, sulfadiazine and the combination of trimethoprim and sulfonamides were active in vitro against cultures of five Batrachochytrium dendrobatidis strains containing sporangia and zoospores, with minimum inhibitory concentrations (MIC) of 0.5-1.0 mu g/ml for florfenicol and 8.0 mu g/ml for the sulfonamides. Trimethoprim was not capable of inhibiting growth but, combined with sulfonamides, reduced the time to visible growth inhibition by the sulfonamides. Growth inhibition of B. dendrobatidis was not observed after exposure to clindamycin, doxycycline, enrofloxacin, paromomycin, polymyxin E and tylosin. Cultures of sporangia and zoospores of B. dendrobatidis strains JEL423 and IA042 were killed completely after 14 days of exposure to 100 mu g/ml florfenicol or 16 mu g/ml trimethoprim combined with 80 mu g/ml sulfadiazine. These concentrations were, however, not capable of efficiently killing zoospores within 4 days after exposure as assessed using flow cytometry. Florfenicol concentrations remained stable in a bathing solution during a ten day period. Exposure of Discoglossus scovazzi tadpoles for ten days to 100 mu g/ml but not to 10 mu g florfenicol/ml water resulted in toxicity. In an in vivo trial, post metamorphic Alytes muletensis, experimentally inoculated with B. dendrobatidis, were treated topically with a solution containing 10 mu g/ml of florfenicol during 14 days. Although a significant reduction of the B. dendrobatidis load was obtained, none of the treated animals cleared the infection. Conclusions: We thus conclude that, despite marked anti B. dendrobatidis activity in vitro, the florfenicol treatment used is not capable of eliminating B. dendrobatidis infections from amphibians.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Emerging therapeutics for the treatment of Friedreich's ataxia
    Indelicato, Elisabetta
    Boesch, Sylvia
    EXPERT OPINION ON ORPHAN DRUGS, 2018, 6 (01): : 57 - 67
  • [32] Generalised Model of Multiphase Tesla's Egg of Columbus and Practical Analysis of 3-Phase Design
    Gezer, Atamer
    Gulbahce, Mehmet Onur
    Kocabas, Derya Ahmet
    ELECTRICA, 2018, 18 (02): : 151 - 158
  • [33] DIOXIDINE - NEW ANTIBACTERIAL DRUG FOR TREATMENT OF PURULENT INFECTION
    PADEISKAYA, EN
    PERSHIN, GN
    KOSTYUCHENOK, BM
    BLATUN, LA
    KULIKOV, YS
    TAGIROV, RF
    GROMOV, MV
    PERSHIN, GG
    MAKARENKOVA, RV
    KHIMIKO-FARMATSEVTICHESKII ZHURNAL, 1977, 11 (08): : 139 - 146
  • [34] Novel Therapeutics for the Treatment of Alzheimer's and Parkinson's Disease
    Singh, Kavita
    Yadav, Dhananjay
    Chauhan, Pallavi S.
    Mishra, Meerambika
    Jin, Jun-O
    CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (07) : 755 - 763
  • [35] Pseudomonas aeruginosa: Burn Infection, Treatment and Antibacterial Resistance
    Japoni, A.
    Farshad, S.
    Alborzi, A.
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2009, 11 (03) : 244 - 253
  • [36] Ridinilazole Antibacterial drug Treatment of Clostridioides difficile infection
    Khanna, S.
    DRUGS OF THE FUTURE, 2019, 44 (05) : 349 - 355
  • [37] CADAZOLID Antibacterial agent Treatment of Clostridium difficile Infection
    Kefauver, S. C.
    DRUGS OF THE FUTURE, 2014, 39 (05) : 325 - 332
  • [38] New Host-Directed Therapeutics for the Treatment of Clostridioides difficile Infection
    Andersson, Jourdan A.
    Peniche, Alex G.
    Galindo, Cristi L.
    Boonma, Prapaporn
    Sha, Jian
    Luna, Ruth Ann
    Savidge, Tor C.
    Chopra, Ashok K.
    Dann, Sara M.
    MBIO, 2020, 11 (02):
  • [39] Treatment of HIV infection and sexually transmitted diseases in Vietnam: A challenge for therapeutics
    Hoang, LMN
    PROCEEDINGS OF THE FORTY-FIFTH ANNUAL MEETING OF THE WESTERN PHARMACOLOGY SOCIETY, 2002, 45 : 235 - 237
  • [40] ERAVACYCLINE Antibacterial agent Treatment of intra-abdominal infection Treatment of complicated urinary tract infection
    Chopra, S.
    Dasgupta, A.
    DRUGS OF THE FUTURE, 2014, 39 (04) : 247 - 256